CliffBio
biologic

Vimizim

elosulfase alfa

Loss of exclusivity—loss of exclusivity
CompanyBiomarin Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand nameVimizim
Active ingredientelosulfase alfa
Strength5MG/5ML (1MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
Marketing statusRx

More from Biomarin Pharmaceutical

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.